Adicet Bio Inc at Canaccord Genuity Growth Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: John Newman - Canaccord Genuity Group Inc. - Analyst : Sure. Thank you. So on that, your lead asset, ADI-001, targets CD20. And I want to make the point CD20 is different than what other CAR-Ts target. Most other CAR-Ts go after CD19. So it's shown an impressive data in non-Hodgkin's lymphoma with a recent clinical update. I wonder if you could talk to us about the Phase 1 results there.

Question: John Newman - Canaccord Genuity Group Inc. - Analyst : Okay, great. And I wonder if we could talk a little bit more about the patients that had previously received CD19 CAR-T. And I want to focus on this group just because people are very focused on initial treatment with CAR-T or bispecifics. But here, you were talking about a patient group that's already failed often CAR-T agents. I'm just curious as to if you could reiterate what you've seen there, and also how that's informing your development pathway. And also, just sort of the competitive landscape in that post CAR-T setting versus prior.

Question: John Newman - Canaccord Genuity Group Inc. - Analyst : Great. And over time, investors have been heavily focused on durability of response for allogeneic or off-the-shelf CAR-T products, and they're always comparing these to autologous CAR-Ts. Wondering if you could talk about how the durability of response for your product compares, roughly speaking, to the autologous CAR-Ts. And we just spoke about the post-CAR-T patients, but just curious overall there.

Question: John Newman - Canaccord Genuity Group Inc. - Analyst : Sure. Also, we -- I wanted to discuss this a little bit more because it's an important point. You mentioned this a few moments ago, but could you talk a little bit more about the response profile and the durability for ADI-001 versus the bispecific agents that are used in large B-cell lymphoma? The reason that I'd like you to elaborate a bit more on this is because I don't feel like investors appreciate the differences here, especially in the post-CAR-T setting that if you get a response with an allogeneic CAR-T like yours, it's not the same as what you get with the bispecific.

Question: John Newman - Canaccord Genuity Group Inc. - Analyst : Are we recording this? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. AUGUST 09, 2023 / 5:00PM, ACET.OQ - Adicet Bio Inc at Canaccord Genuity Growth Conference

Question: John Newman - Canaccord Genuity Group Inc. - Analyst : Great. Thank you. And ADI-001 is advancing to a potentially pivotal Phase 2 study in post-CAR-T large B-cell lymphoma, I believe, in the first half of 2024. Could you talk a bit about the design of this study? And also, could you talk about the importance of going after a different target? So going after -- initially, you're being treated with a CAR-T against CD19, you're not just repeating that, you're going after a completely different target.

Question: John Newman - Canaccord Genuity Group Inc. - Analyst : Okay, great. I believe you will be presenting some additional data for ADI-001, I think, perhaps in the second half of next year. This is more follow-up, but curious as to the type of data we might see there.

Question: John Newman - Canaccord Genuity Group Inc. - Analyst : Another question here. So as we know, ADI-001 is an off-the-shelf allogeneic product that does not have to be made custom for each patient. Curious, longer-term here, is there any reason that you might test ADI-001, which targets CD20 ahead of a CD19 CAR-T? I'm just curious if that's ever been contemplated, or perhaps maybe in the future it might be investigated.

Question: John Newman - Canaccord Genuity Group Inc. - Analyst : Okay, great. And you also have a TCR, like platform for intercellular solid tumor targets, for example. Could you talk about the platform and any potential targets that you've identified or how that might proceed going forward?

Question: John Newman - Canaccord Genuity Group Inc. - Analyst : Sure. Actually, that was my next question. Wondering if you could take us through the initial plans for the CD70 program. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. AUGUST 09, 2023 / 5:00PM, ACET.OQ - Adicet Bio Inc at Canaccord Genuity Growth Conference

Question: John Newman - Canaccord Genuity Group Inc. - Analyst : Excellent. It's actually, all the time that we have today. I wish you could actually speak about some of the other pipeline programs. But Chen, I thank you very much, and thank you to Adicet for joining us today.